J&J receives three subpoenas

Share this article:
Johnson & Johnson has received separate subpoenas from US Attorney’s Offices in Philadelphia, Boston and San Francisco related to marketing of three prescription drugs. The drugs at issue are schizophrenia and bipolar treatment Risperdal, marketed by Janssen, epilepsy treatment Topamax by Ortho-McNeil and heart-failure drug Natrecor by Scios. The investigations have been previously disclosed. The latest subpoenas seek information concerning corporate supervision and oversight of the J&J subsidiaries, which sell the drugs. The new subpoenas arrived at J&J’s corporate headquarters late last week, according to published reports. J&J said it plans to cooperate in responding to the subpoenas.
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.